EHA2025
Advertisement
Immunotherapy is reshaping ALL care, and short blinatumomab use may boost outcomes and reduce chemo-related toxicity.
In the SURPASS ET trial, ropeginterferon alfa-2b was compared to anagrelide in second-line management of ET.
A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.
Advertisement
Dr. O’Brien described the safety and efficacy of zanubrutinib and the benefits of combining the drug with other agents.
Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.
Dose escalation study data presented at EHA2025 showed durable response in patients with disease resistant to prior therapy.
Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.
Mosun SC shows positive ORR and CMR rates in first-line MZL, offering an effective, outpatient-friendly treatment option.
Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.
Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.
Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.
Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
EHA 2025 unites global hematology experts to learn, connect & advance care—June 12–16 in Milan, Italy.
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.